Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia

Table 5 Mean changes in SF-12 PCS and MCS scores

		Core Study Baseline	Extension Study Baseline (6 weeks)	Extension Study Endpoint (end of additional 24 weeks of treatment)
	N	143^a	143^b	97^c
PCS Score	Mean Score (SD)	46.5 (10.6)	46.3 (10.1)	48.6 (9.4)
	Change from Core Baseline (SD)	--	−0.3 (8.4)	2.6 (7.9)
	p-value	--	0.629	0.001
MCS Score	Mean Score (SD)	41.8 (11.1)	46.5 (11.2)	47.3 (9.6)
	Change from Core Baseline (SD)	--	4.8 (11.6)	6.3 (10.3)
	p-value	--	<0.001	<0.001

Abbreviations: MCS Mental Component Summary, PCS Physical Component Summary, SD standard deviation, SF-12 Short Form-12
^aNumber of patients with SF-12 PCS and MCS scores at core study baseline
^bNumber of patients with SF-12 PCS and MCS scores at both core study baseline and extension study baseline
^cNumber of patients with SF-12 PCS and MCS scores at both core study baseline and extension study endpoint

ISSN: 1471-244X